Sumitomo Dainippon Pharma Co., Ltd. provided financial guidance for the year ending March 31, 2023. For the period, the company expected Net sales of JPY 550,000 million, Operating profit of JPY 24,000 million, Net profit attributable to owners of parent of JPY 22,000 million and EPS of JPY 55.37.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
328 JPY | +7.54% | +9.70% | -29.61% |
May. 14 | Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024 | |
May. 14 | Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.61% | 771M | |
+40.73% | 739B | |
+31.57% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.70% | 240B | |
+9.28% | 210B | |
-5.07% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2023